The New England journal of medicine 2018-01-11
Osimertinib in Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer.
ABSTRACT
BACKGROUND
Osimertinib is an oral, third-generation, irreversible epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) that selectively inhibits both EGFR-TKI-sensitizing and EGFR T790M resistance mutations. We compared osimertinib with standard EGFR-TKIs in patients with previously untreated, EGFR mutation-positive advanced non-small-cell lung cancer (NSCLC).
METHODS
In this double-blind, phase 3 trial, we randomly assigned 556 patients with previously untreated, EGFR mutation-positive (exon 19 deletion or L858R) advanced NSCLC in a 1:1 ratio to receive either osimertinib (at a dose of 80 mg once daily) or a standard EGFR-TKI (gefitinib at a dose of 250 mg once daily or erlotinib at a dose of 150 mg once daily). The primary end point was investigator-assessed progression-free survival.
RESULTS
The median progression-free survival was significantly longer with osimertinib than with standard EGFR-TKIs (18.9 months vs. 10.2 months; hazard ratio for disease progression or death, 0.46; 95% confidence interval [CI], 0.37 to 0.57; P<0.001). The objective response rate was similar in the two groups: 80% with osimertinib and 76% with standard EGFR-TKIs (odds ratio, 1.27; 95% CI, 0.85 to 1.90; P=0.24). The median duration of response was 17.2 months (95% CI, 13.8 to 22.0) with osimertinib versus 8.5 months (95% CI, 7.3 to 9.8) with standard EGFR-TKIs. Data on overall survival were immature at the interim analysis (25% maturity). The survival rate at 18 months was 83% (95% CI, 78 to 87) with osimertinib and 71% (95% CI, 65 to 76) with standard EGFR-TKIs (hazard ratio for death, 0.63; 95% CI, 0.45 to 0.88; P=0.007 [nonsignificant in the interim analysis]). Adverse events of grade 3 or higher were less frequent with osimertinib than with standard EGFR-TKIs (34% vs. 45%).
CONCLUSIONS
Osimertinib showed efficacy superior to that of standard EGFR-TKIs in the first-line treatment of EGFR mutation-positive advanced NSCLC, with a similar safety profile and lower rates of serious adverse events. (Funded by AstraZeneca; FLAURA ClinicalTrials.gov number, NCT02296125 .).
Related Questions
Can SRS or whole brain radiotherapy be reserved for progression in these young, healthy patients?
New answer by Radiation Oncologist at Levine Cancer Institute (June 8, 2018)
I think the answers to this question above make some great points. However, old data on this topic are now a bit outdated with the recent results of the FLAURA trial which mov...
http://abstracts.asco.org/239/AbstView_239_262655.html
New comment by Medical Oncologist at Sarah Cannon Cancer Institute at Menorah Medical Center ( June 7, 2019)
In the settings where Osi is not available, the use of first generation EGFR inhibitors, in my opinion, should be considered in combination with a VEGF inhibitor or chemothera...
With low #s of patients on the durvalumab PACIFIC trial with EGFR mutated disease, and LAURA trial design of osimertinib until progression, should we ...
New answer by Radiation Oncologist at Vanderbilt-Ingram Cancer Center (November 26, 2024)
The tough answer is that Osi after chemoRT improves PFS without significant OS benefit based on current data. Thus, is there any advantage of doing consolidative indefinite Os...